On November 4, 2021 Targovax ASA (the "Company") reported that regarding the resolution by the Company’s board of directors to propose that the Company carries out a share capital increase, by way of a fully underwritten rights issue, to raise gross proceeds of NOK 175 million (the "Rights Issue") (Press release, Targovax, NOV 4, 2021, View Source [SID1234594410]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date on which the terms and conditions of the preferential rights issue were announced: 4 November 2021
Last day including right: 25 November 2021
Ex-date: 26 November 2021
Record Date: 29 November 2021
Date of approval: 25 November 2021
Maximum number of new shares: 350,000,000
Subscription price: Minimum NOK 0.50 and maximum NOK 10.00
Ratio preferential rights: To be announced when final number of new shares is determined
Subscription ratio: To be announced when final number of new shares is determined
Managers: Carnegie AS and DNB Markets, a part of DNB Bank ASA
Will the rights be listed: The Company will apply for listing of the preferential rights on the Oslo Stock Exchange
ISIN for the preferential rights: To be announced when clarified
Other information: The subscription price for the new shares to be issued in the Rights Issue, and thus the final number of new shares and the exact amount of the share capital increase will be proposed by the board of directors, based on a recommendation from the Managers, the day prior to the extraordinary general meeting to be held on 25 November 2021 (the "EGM"). See the stock exchange announcement containing the notice to the EGM published earlier today, on 4 November 2021, for further information regarding the Rights Issue. The rights issue is subject to approval by the EGM.
This information is published in accordance with the requirements of the Continuing Obligations.